Antibody Information
General Information of This Antibody
| Antibody ID | ANI0DNMCK |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-ALPPL2 mAb M25 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Alkaline phosphatase, germ cell type (ALPG) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
M25ADCMMAF [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 62.30% (Day 31) | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 150 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for a total of 4 doses at 5 mg/kg.
|
||||
| In Vivo Model | M28 CDX model | ||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 69.16% (Day 32) | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 250 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for a total of 4 doses at 5 mg/kg.
|
||||
| In Vivo Model | M28 CDX model | ||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.72% (Day 37) | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 500 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for a total of 4 doses at 5 mg/kg.
|
||||
| In Vivo Model | M28 CDX model | ||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.40 nM
|
Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
36.00 nM
|
Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Pleural sarcomatoid mesothelioma | VAMT-1 cells | CVCL_A731 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Normal | HK-2 [Human kidney] cells | CVCL_0302 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Normal | HS775Li cells | Homo sapiens | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Normal | HS-27 cells | CVCL_0E34 | ||
M25ADCMMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.73% (Day 45) | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 250 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for 3 mg/kg very four days for a total of 5 doses.
|
||||
| In Vivo Model | M28 CDX model | ||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.89% (Day 45) | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 250 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for 5 mg/kg very four days for a total of 5 doses.
|
||||
| In Vivo Model | M28 CDX model | ||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.30 nM
|
Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Pleural malignant mesothelioma | M28K cells | CVCL_8106 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.44 nM
|
Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Pleural sarcomatoid mesothelioma | VAMT-1 cells | CVCL_A731 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Normal | HK-2 [Human kidney] cells | CVCL_0302 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Normal | HS775Li cells | Homo sapiens | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Positive ALPPL2 expression (ALPPL2+++/++) | ||
| Method Description |
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
|
||||
| In Vitro Model | Normal | HS-27 cells | CVCL_0E34 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.